Early results suggest Paxil birth defect risk

Early results of new studies suggest GlaxoSmithKline Plc’s antidepressant Paxil increases the risk of birth defects when women take it during the first three months of Pregnancy, the U.S. Food and Drug Administration said on Thursday.

“FDA is advising patients that this drug should usually not be taken during Pregnancy, but for some women who have already been taking Paxil, the benefits of continuing may be greater than the potential risk to the fetus,” the FDA said in a statement.

Preliminary findings from two studies showed women who took Paxil during the first three months of Pregnancy were about 1.5 to 2 times as likely to have a baby with a heart defect as women who took other antidepressants, or women in the general population, the FDA said.

GlaxoSmithKline added data from one of the studies to Paxil’s prescribing information in September and since then has added details from the second study, the FDA said.

Shares of GlaxoSmithKline were down less than 1 percent in London trading. The company’s shares were up 53 cents, or 1 percent, to $50.70 in morning trade on the New York Stock Exchange. 

Print Version
Tell-a-Friend

RELATED ARTICLES:

Moderate Use May Avert Failure of Type 2 Diabetes Drugs   Rutgers researchers identify new antibiotic target and new antibiotic mechanism   Genes affect weight loss drug effectiveness   No mental effects seen with Arimidex   Guide helps doctors manage vaccine allergies   Class of Diabetes Drugs Carries Significant Cardiovascular Risks   Medication improves alcoholics’ quality of life   Experimental drug lowers blood sugar in diabetics   Higher co-payments reduce use of antidepressants   Synthetic molecules hold promise for new family of anti-cancer drugs   Search for an HIV Vaccine Must Go On Says Expert in Light of Recent High-profile Merck Failure   When one antidepressant doesn’t work, another may